Apabetalone did not reduce MACE risk in patients of ACS with diabetes

Researchers have found that Apabetalone did not significantly reduce major adverse cardiovascular events after acute coronary syndrome with Type 2 diabetes.The study has been published in the journal of American Medical Association.

Apabetalone is a selective bromodomain and extraterminal protein inhibitor targeting bromodomain 2 and is hypothesized to have potentially favorable effects on pathways related to atherothrombosis.

The researchers conducted a randomized, double-blind, placebo-controlled trial involving patients with recent acute coronary syndrome (preceding 7 to 90 days), type 2 diabetes, and low high-density lipoprotein cholesterol levels to investigate whether apabetalone significantly decreases major adverse cardiovascular events or not.

The study was conducted at 190 sites in 13 countries. Participants were randomized (1:1) to receive either apabetalone 100 mg orally twice daily (n = 1,215) or matching placebo (n = 1,210) in addition to standard care. A composite of time to the first occurrence of cardiovascular death, nonfatal myocardial infarction, or stroke was considered as the primary outcome. Researchers found no significant reduction in the risk of major adverse cardiovascular events was brought about by apabetalone added to standard therapy in this patient population.

The researchers concluded that among patients with recent acute coronary syndrome, type 2 diabetes, and low high-density lipoprotein cholesterol levels, the selective bromodomain and extraterminal protein inhibitor apabetalone added to standard therapy did not significantly reduce the risk of major adverse cardiovascular events.

For further reference log on to:

JAMA. 2020;323(16):1565-1573. doi:10.1001/jama.2020.3308